The underlying mechanisms of antipsychotic (AP)-induced weight gain are unknown, but both central and peripheral AP target receptors could potentially be involved. This study used radioligand binding assays to compare the binding affinities of clozapine, olanzapine and haloperidol for candidate receptors potentially involved in AP-induced weight gain. Selected candidates derived from known pathways involved in body weight regulation included receptors classified as anorexigenic (bombesin receptor subtype 3, calcitonin gene-related peptide receptor, cholecystokinin receptor, melanocortin-4 receptor, neurotensin receptor 1) or orexigenic (cannabinoid receptor 1, galanin 1 receptor, melanin-concentrating hormone receptor (MCHR), neuropeptide Y1 receptor) as well as receptors involved in physiological actions related to digestion and fluid homeostasis (angiotensin II type 1 receptor, bradykinin B2 receptor, endothelin receptor, neurokinin 1 receptor, vasoactive intestinal polypeptide receptor 1). Clozapine, olanzapine and haloperidol exhibited negligible affinities to all of these receptors except for the MCHR (K i ¼ 501 nM; haloperidol). With respect to other candidates from (neuro)transmitter systems already suggested to be involved in AP-induced weight gain, the binding profile of olanzapine resembled that of clozapine, with high affinity (K i o10 nM) for serotonin (5-HT) 5-HT 2A , 5-HT 2C and 5-HT 6 , muscarinic M1 and histamine H1 receptors. In contrast, the binding profile of haloperidol was substantially different (high affinity only for the dopamine D1 receptor). In conclusion, we have not identified a novel binding site of the two investigated atypical AP that could contribute to the induced weight gain.
Introduction
Weight gain occurs in up to 50% of patients under chronic administration of antipsychotics (AP). 1 Weight gain not only impairs physical health but also reduces treatment compliance and may cause adverse psychosocial consequences. Although there is generally marked variability in incidence and severity of weight gain among the various AP, especially the atypical AP clozapine and olanzapine are associated with this side effect. [1] [2] [3] The underlying mechanisms are unknown, but genetic factors are seemingly involved. 4 In clinical studies, clozapine has been associated with increments in appetite, carbohydrate craving 5 and binge eating episodes, [6] [7] [8] suggesting a change in energy intake. Currently, the effects of AP on energy expenditure have been less well studied. In prospective clinical studies, olanzapine-induced weight gain was associated with an increase in caloric intake, 9 whereas resting energy expenditure did not change over the observation periods of four 9 and 12 10 weeks. In contrast, an observation in three patients treated with clozapine revealed a reduction of resting metabolic rates by 10.3-16.0% within 1 month. 11 Because AP bind to many neurotransmitter receptors in human brain, the multiple therapeutic and adverse effects of various AP may depend on the combination of receptors occupied. 12 The effect of genetic variation of diverse candidate receptor genes implicated in weight gain has been investigated. [13] [14] [15] [16] [17] [18] [19] [20] For example, the À759C/T polymorphism of the serotonin (5-HT) 5-HT 2C receptor gene was studied in patients with weight gain upon use of clozapine 14, [18] [19] [20] [21] or other AP. 17, 22, 23 However, as yet unknown pharmacodynamic (including both central and peripheral AP target receptors) and pharmacokinetic (i.e. enzymes that metabolize AP) factors may be involved in AP-induced weight gain. So far, research into this side effect was based on the binding profiles of AP and has thus primarily focused on classical neurotransmitter receptors such as dopaminergic, serotonergic, histaminergic, muscarinic and/or adrenergic receptors; the role of peripherally and centrally acting hormones and peptides involved in body weight regulation is largely unknown. 1, 3, 13, 15, 16 Factors implicated in the susceptibility to clozapine-or olanzapine-related weight gain include leptin 6,24-26 and ghrelin. [26] [27] [28] We found no evidence for a direct peripheral effect of clozapine on fat-cell formation or production of leptin and other fat-cell-derived factors. 29 The increase in serum leptin levels under treatment with AP is most likely secondary to weight gain and seemingly not mechanistically involved. 25 Additionally, other changes in biological parameters related to body weight, such as tumor necrosis factoralpha (TNF-alpha), soluble TNF receptors and interleukin-6 (IL-6) may be involved in AP-induced weight gain. 30 The rapidly evolving knowledge derived from molecular obesity research benefits the identification of peripherally and centrally acting hormones and peptides involved in body weight regulation and/or fluid homeostasis. The investigation of such peptides and receptors involved in body weight regulation may be a promising approach to investigate the mechanisms potentially underlying AP-induced weight gain. Candidates derived from known pathways involved in body weight regulation include receptors classified as anorexigenic (such as bombesin receptor subtype 3, calcitonin gene-related peptide receptor, cholecystokinin receptor, melanocortin-4 receptor, neurotensin receptor 1) 31, 32 or orexigenic (such as cannabinoid receptor 1, galanin 1 receptor, melanin-concentrating hormone receptor (MCHR), neuropeptide Y1 receptor). 31, 33 Additionally, it could be speculated that receptors involved in physiological actions related to digestion and fluid homeostasis (such as angiotensin II type 1 receptor, bradykinin B2 receptor, endothelin receptor, neurokinin 1 receptor, vasoactive intestinal polypeptide receptor 1) [34] [35] [36] [37] [38] could be involved in weight changes observed under treatment with AP.
In the present article, we have attempted to investigate the potential involvement of several central and peripheral receptors in AP-induced weight gain by using commercially available radioligand binding assays (CEREP, 86600 Celle l' Evescault, France). It was hypothesized that the differential binding profiles of typical and atypical AP may contribute to differences demonstrated with respect to weight gain. We therefore explored the binding affinities of clozapine and olanzapine in comparison with those of haloperidol, a typical AP that causes relatively low weight gain. 2, 3 Based on the CEREP offer, we chose (1) receptors of diverse peripherally and centrally acting hormones and peptides derived from known pathways involved in body weight regulation and related to digestion and fluid homeostasis; (2) receptors of other candidates from (neuro)transmitter systems already suggested to be involved in AP-induced weight gain.
Materials and methods
Radioligand binding assays were performed at CEREP, Poitiers, France and included (1) 14 potential candidates known from pathways involved in body weight regulation or related to digestion and fluid homeostasis (see Table 1 ) as well as (2) 17 candidates of the serotonergic, dopaminergic, muscarinic, histaminergic and adrenergic transmitter systems (see Table 2 ).
The binding assay methods are summarized in Supplementary Table 1 . Following incubation, the membranes or cells in suspension were rapidly filtered under vacuum through glass fiber filters (GF/B, Packard or Filtermat A or B, Wallac (now PerkinElmer, Inc., Boston, MA, USA)). Filters were then washed several times with an ice-cold buffer using a cell harvester (Packard or Tomtec). Bound radioactivity was measured with a scintillation counter (Topcout, Packard or Betaplate, Wallac) using a liquid scintillation cocktail (Microscint 0, Packard) or a solid scintillant (MeltiLex B/HS, Wallac).
Experimental protocols
The three test compounds (clozapine, haloperidol HCL, olanzapine) were dissolved at 1 mM in dimethylsulfoxide (DMSO) and shipped to CEREP. The compounds were first tested in all assays at 1 mM. If the compounds caused more than 50% inhibition of the specific binding at this concentration, they were further tested at 0.1 mM. If they again inhibited more than 50% of the specific binding at this concentration, they were finally tested at 0.01 mM. Each determination was made in duplicate. In each experiment, the respective reference compound was tested at a minimum of eight concentrations in duplicate to obtain a competition curve in order to validate the experiment.
Analysis and expression of results
The specific radioligand binding to the receptors is defined as the difference between total and nonspecific binding determined in the presence of an unlabelled ligand. IC 50 values (concentration causing a half-maximal inhibition of control specific binding) and Hill coefficients (nH) were determined for the reference compounds by nonlinear regression analysis of their competition curves. These parameters were obtained by Hill equation curve fitting. The IC 50 values obtained for the reference compounds are within accepted limits of historic averages obtained 70.5 log unit. The IC 50 values were converted to the affinity constants (K i values) by application of the Cheng-Prusoff equation:
where L is the concentration of radiolabelled ligand (agonist or antagonist) and K d is its affinity for the receptor of the membrane preparation. 39 Comparison to binding data derived from the literature In order to compare the results of our study to binding data derived from the literature, a review of published binding data that integrates data from different sources, including Medline/PubMed and websites such as the 'Information system for G protein-coupled receptors (GPCRs)', 40 was performed. Because findings across studies vary significantly in methodology, with the use of different receptor/tissue sources, radioligands, or in vitro assay conditions, we converted the binding data from the literature 40-59 into semiquantitative categories (no or low affinity, moderate affinity, high affinity; see Table 2 ) to provide better comparability.
Results
The radioreceptor binding affinities of clozapine, olanzapine and haloperidol for the candidates derived from known pathways involved in body weight regulation (Table 1) 31-38 were all negligible (K i o1000 nM), with the exception of the MCHR (K i ¼ 501 nM; haloperidol).
The Table 2) . [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] The binding profile of olanzapine resembled that of clozapine, 13, 15, 16 This study primarily aimed at investigating the binding affinities of the atypical AP clozapine and olanzapine in comparison with the typical AP haloperidol for selected candidate receptors for AP-induced weight gain.
First, we investigated selected candidates derived from the known pathways involved in body weight regulation. These included receptors for ligands with anorexigenic and orexigenic action as well as receptors involved in physiological actions related to digestion and fluid homeostasis (see Table 1 ). With the exception of the MCHR, to which low affinity binding of haloperidol was detected (K i ¼ 501 nM), clozapine, olanzapine and haloperidol exhibited negligible affinities to all other receptors. The results suggest that these candidate receptors do not play a significant part in the direct pharmacological action of clozapine, olanzapine and haloperidol. However, research into specific physiological roles of neuropeptides has remained elusive after several decades of research, but transmitter-like, trophic and modulatory actions are seen for most peptides. Thus, because of multiple interactions, an indirect involvement of these central and peripheral AP target receptor systems in AP-induced weight gain cannot be excluded. Finally, it remains possible that AP bind to distinct receptors involved in weight regulation, which were not investigated in the current study.
Second, we investigated candidates from (neuro)transmitter systems already suggested to be involved in AP-induced weight gain (see Table 2 ). With respect to these receptors, the binding profile of olanzapine resembled that of clozapine, with high affinity for serotonin 5-HT 2A and 5-HT 6 , muscarinic M 1 
40-59
Origin/tissue is not specified here because the receptor-binding affinities for haloperidol, clozapine and olanzapine, respectively, were quite similar in different tissues.
Candidate receptors for antipsychotic-induced weight change FM Theisen et al presentation of published receptor binding properties is beyond the scope of this study. However, on the basis of our review integrating data from different sources, we did not find significant differences between our binding data and results derived from other studies. Certainly, caution is warranted in comparing findings across studies that vary significantly in methodology and it is important to note that some inconsistencies exist in the receptor-binding data reported in the literature. Nonetheless, the research done thus far has yielded certain consistent general properties that are useful to consider at a clinical level.
The differing action of AP on the serotonergic, dopaminergic, cholinergic, g-amino butyric acid (GABA)-ergic, histaminergic and other neurotransmitter systems has been hypothesized to be involved in weight gain. 1, [60] [61] [62] In their clinical investigation of weight changes under the AP clozapine, olanzapine, risperidone, sertindole and haloperidol, Wirshing et al. 3 found, based on the known receptorbinding properties of these drugs, an exponential association between the histamine H 1 receptor affinity and the weight gain is observed in the patients. The serotonin 5-HT 2 receptor, another plausible candidate for this side effect, was not associated with weight gain. Kroeze et al. 59 investigated the binding properties of 17 typical and atypical AP (including clozapine, olanzapine and haloperidol) towards 12 neurotransmitter receptors and correlated the results with short-term weight gain data (derived from Allison et al.
2 ). They found that the receptor affinities of histamine H 1 , adrenaline a 1A , serotonin 5-HT 2C and 5-HT 6 receptors, respectively, were significantly correlated with weight gain, whereas the eight other receptor's affinities were not (adrenaline a 2A , a 2B and a 2C ; serotonin 5-HT 1A , 5-HT 2A and 5-HT 7 ; dopamine D 2 ; muscarinic M 3 ). Although there are some differences with respect to the methods and the receptors investigated, these findings are widely in line with our results indicating an association of the histamine H 1 and the serotonin 5-HT 2C and 5-HT 6 receptors with AP-induced short-term weight gain, 2 while the muscarinic M 3 receptor does not seem to play a major role in this side effect.
There are some pharmacological clues, which suggest that the serotonergic and histaminergic systems may play a role in clozapine-induced weight gain. 13, 15, 16 Studies involving polymorphisms of the serotonin 5-HT 1A , 5-HT 2A , 5-HT 2C , 13,63 5-HT 6 receptor genes, 5-HT transporter gene, 63 and the histamine H 1 and H 2 receptor genes 13 have failed to demonstrate genotype effects on clozapine-induced weight gain. The finding of a significant association between a À759C/T polymorphism of the 5-HT 2C receptor gene and weight gain induced by diverse AP (mostly chlorpromazine and risperidone) 17 or by clozapine 18 could not be confirmed by three independent studies involving clozapine. 14, 19, 20 However, sample characteristics and differences in observation period between studies may play a role. Recent studies in acutely ill (olanzapine 23 ) or first episode (mostly olanzapine and risperidone 22 ) patients and those followed in longer-term studies (6 months; 21 9 months 22 ) showed that carriers of the À759T allele gained significant less weight. The À759C/T polymorphism of the 5-HT 2C receptor gene is of interest because the À759C allele is functionally active. 64 In conclusion, the current results suggest that the selected candidate receptors derived from known pathways involved in body weight regulation (Table 1) do not play a significant part in the direct pharmacological action of clozapine, olanzapine and haloperidol. With respect to other candidates from (neuro)transmitter systems already suggested to be involved in AP-induced weight gain (Table 2) , our results confirm binding data from the literature indicating an involvement of the serotonin 5-HT 2A , 5-HT 2C and 5-HT 6 , muscarinic M 1 and/or histamine H 1 receptors in this side effect. So far, research into AP-induced weight gain has primarily focused on neurotransmitter receptors. Much less is known about other receptor systems and AP effects. We believe that the systematic investigation of the role of peripherally and centrally acting hormones and peptides involved in body weight regulation may be a promising approach to investigate the mechanisms potentially underlying AP-induced weight gain. In this context, the rapidly evolving knowledge derived from molecular obesity research may benefit the identification of potential candidates for this side effect. Further studies are necessary to understand the implication and the possible cross-talk between the diverse transmitter systems potentially involved in APinduced weight gain.
